| [1] |
Hunter DJ, Bierma-Zeinstra S
. Osteoarthritis. Lancet
2019
;
393
(
10182
):
1745
−
59
.
|
| [2] |
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al
. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol
2020
;
72
(
2
):
220
−
33
.
|
| [3] |
Wood E, Simel DL, Klimas J
. Pain management with opioids in 2019-2020. JAMA
2019
;
322
(
19
):
1912
−
13
.
|
| [4] |
Sicras-Mainar A, Tornero-Tornero C, Vargas-Negrín F, Lizarraga I, Rejas-Gutierrez J. Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study. Ther Adv Musculoskelet Dis 2020;12:1759720X20942000. http://dx.doi.org/10.1177/1759720X20942000.
|
| [5] |
Villanueva MT
. Designing out opioid side effects. Nat Rev Drug Discov
2017
;
16
(
5
):
311
.
|
| [6] |
Budenholzer B
. Nonopioids and opioids gave similar relief for back pain or osteoarthritis but nonopioids had fewer adverse effects. Ann Intern Med
2018
;
168
(
12
):
JC64
.
|
| [7] |
Krebs EE, Gravely A, Nugent S, Jensen AC, Deronne B, Goldsmith ES, et al
. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA
2018
;
319
(
9
):
872
−
82
.
|
| [8] |
da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al
. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ
2021
;
375
:
n2321
.
|
| [9] |
Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, et al
. Opioids for osteoarthritis: cross-sectional survey of patient perspectives and satisfaction. J Clin Med
2023
;
12
(
7
):
2733
.
|
| [10] |
Gorfinkel L, Voon P, Wood E, Klimas J
. Diagnosing opioid addiction in people with chronic pain. BMJ
2018
;
362
:
k3949
.
|